^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ROS1 mutation

i
Other names: ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Entrez ID:
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
04/22/2024
Initiation :
10/07/2022
Primary completion :
12/31/2027
Completion :
12/31/2027
EGFR • PD-L1 • ALK • ROS1
|
PD-L1 expression • ALK mutation • ROS1 mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
Phase 2
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
04/09/2024
Initiation :
08/15/2019
Primary completion :
10/01/2024
Completion :
06/01/2025
KRAS • BRAF • ER • PGR • ROS1 • NTRK
|
HER-2 positive • EGFR mutation • HER-2 negative • ROS1 mutation • BRAF positive
|
Rozlytrek (entrectinib) • Verzenio (abemaciclib) • Krazati (adagrasib) • paxalisib (GDC-0084)
Phase 1/2
NeoImmuneTech
Active, not recruiting
Last update posted :
03/15/2024
Initiation :
06/10/2020
Primary completion :
11/05/2024
Completion :
03/31/2025
BRAF • ALK • ROS1
|
EGFR mutation • BRAF mutation • ALK translocation • ROS1 mutation
|
Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)
Phase 1/2
Coherus Biosciences, Inc.
Active, not recruiting
Last update posted :
02/20/2024
Initiation :
04/26/2023
Primary completion :
01/01/2026
Completion :
01/01/2026
EGFR • PD-L1 • ALK • MET • ROS1
|
EGFR mutation • ALK mutation • MET mutation • ROS1 mutation
|
Loqtorzi (toripalimab-tpzi) • CHS-006
Phase 1
Palobiofarma SL
Active, not recruiting
Last update posted :
02/09/2024
Initiation :
10/01/2018
Primary completion :
05/01/2024
Completion :
08/01/2024
EGFR • ALK • ROS1
|
ALK mutation • ROS1 mutation
|
PBF-1129
Phase N/A
Hunan Province Tumor Hospital
Recruiting
Last update posted :
12/27/2023
Initiation :
03/24/2020
Primary completion :
12/24/2024
Completion :
12/24/2025
EGFR • ALK • ROS1
|
EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation
Phase 1/2
Roswell Park Cancer Institute
Recruiting
Last update posted :
11/08/2023
Initiation :
12/22/2016
Primary completion :
12/09/2027
Completion :
12/09/2027
PD-L1 • KRAS • ALK • ROS1
|
PD-L1 expression • ALK mutation • ROS1 mutation
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
11/03/2023
Initiation :
04/04/2016
Primary completion :
10/04/2023
Completion :
10/11/2024
PD-L1 • BRAF • ALK • ROS1 • CD4
|
BRAF V600 • ALK mutation • ROS1 mutation
|
Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
Phase 2
Wake Forest University Health Sciences
Completed
Last update posted :
10/12/2023
Initiation :
05/01/2015
Primary completion :
04/19/2018
Completion :
10/07/2022
EGFR • ALK • ROS1
|
ROS1 mutation
|
pemetrexed
Phase 2
Chongqing University Cancer Hospital
Not yet recruiting
Last update posted :
09/26/2023
Initiation :
11/01/2023
Primary completion :
11/30/2024
Completion :
05/31/2026
EGFR • ALK • ROS1
|
EGFR mutation • ALK mutation • ROS1 mutation
|
AiRuiKa (camrelizumab) • capecitabine • AiRuiYi (fluzoparib)
Phase 3
Shanghai Henlius Biotech
Active, not recruiting
Last update posted :
08/08/2023
Initiation :
12/02/2019
Primary completion :
10/01/2023
Completion :
03/15/2024
PD-L1 • ALK • TMB • MSI • ROS1
|
PD-L1 expression • ALK mutation • ROS1 mutation
|
carboplatin • pemetrexed • Hansizhuang (serplulimab) • Hanbeitai (bevacizumab biosimilar)
Phase N/A
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
05/22/2023
Initiation :
09/28/2020
Primary completion :
09/15/2025
Completion :
09/15/2025
EGFR • HER-2 • PD-L1 • KRAS • BRAF • ALK • MET • ROS1
|
PD-L1 expression • KRAS mutation • EGFR mutation • BRAF mutation • MET mutation • ALK translocation • ROS1 mutation
|
Opdivo (nivolumab)
Phase 1/2
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recruiting
Last update posted :
12/09/2022
Initiation :
04/28/2022
Primary completion :
12/01/2023
Completion :
06/01/2024
EGFR • ALK • ROS1 • HAVCR2
|
PD-L1 expression • ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
|
benmelstobart (APL-502) • TQB2618
Phase 1/2
Ludwig Institute for Cancer Research
Completed
Last update posted :
10/10/2022
Initiation :
12/20/2017
Primary completion :
10/29/2021
Completion :
10/29/2021
EGFR • ALK • ROS1
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Imfinzi (durvalumab) • Imjudo (tremelimumab) • BI 1361849 • self-amplifying RNA cancer vaccine
Phase N/A
University of Colorado, Denver
Withdrawn
Last update posted :
09/21/2022
Initiation :
01/06/2022
Primary completion :
09/15/2022
Completion :
09/15/2022
EGFR • ALK • ROS1
|
EGFR mutation • ALK rearrangement • ALK mutation • ROS1 rearrangement • ROS1 mutation • ALK amplification
Phase 2
Sameek Roychowdhury
Withdrawn
Last update posted :
02/18/2022
Initiation :
03/20/2019
Primary completion :
11/20/2020
Completion :
12/30/2021
ALK • ROS1
|
ALK fusion • ALK mutation • ROS1 fusion • ROS1 mutation
|
Alunbrig (brigatinib)
Phase 2
Tang-Du Hospital
Recruiting
Last update posted :
09/24/2021
Initiation :
08/31/2021
Primary completion :
08/31/2023
Completion :
12/31/2023
EGFR • ALK • ROS1
|
EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type
|
cisplatin • carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
Phase 2
The First Affiliated Hospital with Nanjing Medi...
Recruiting
Last update posted :
08/12/2021
Initiation :
06/01/2021
Primary completion :
05/01/2023
Completion :
05/01/2023
ALK • ROS1
|
ALK mutation • ROS1 mutation
|
cisplatin • carboplatin • paclitaxel • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • pemetrexed
Phase 1/2
NKMAX Co., Ltd.
Recruiting
Last update posted :
07/21/2021
Initiation :
07/08/2021
Primary completion :
05/26/2023
Completion :
05/26/2023
EGFR • ALK • ROS1
|
EGFR mutation • ALK mutation • ROS1 mutation
|
Erbitux (cetuximab) • carboplatin • gemcitabine • SNK01
Phase 1/2
Chinese Academy of Medical Sciences
Unknown status
Last update posted :
08/17/2018
Initiation :
08/15/2018
Primary completion :
08/14/2019
Completion :
08/14/2020
EGFR • ALK • ROS1
|
EGFR mutation • ALK mutation • ALK wild-type • ROS1 mutation • ROS1 wild-type
|
carboplatin • paclitaxel • Focus V (anlotinib) • pemetrexed
Phase N/A
First People's Hospital of Hangzhou
Unknown status
Last update posted :
10/27/2016
Initiation :
11/01/2016
Primary completion :
11/01/2017
Completion :
11/01/2018
EGFR • ALK • MET • ROS1
|
EGFR wild-type • ALK mutation • MET mutation • ROS1 mutation